keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer, circulating tumor cells

keyword
https://www.readbyqxmd.com/read/28337998/circulating-tumor-cell-status-monitors-the-treatment-responses-in-breast-cancer-patients-a-meta-analysis
#1
Wen-Ting Yan, Xiang Cui, Qing Chen, Ya-Fei Li, You-Hong Cui, Yan Wang, Jun Jiang
Whether circulating tumor cells (CTCs) can be used as an indicator of treatment response in breast cancer (BC) needs to be clarified. We addressed this issue by a meta-analysis. PubMed, EMBase and Cochrane library databases were searched in June 2016. Effect measures were estimated as pooled risk ratio (RR), odds ratio (OR) or mean difference by fixed- or random-effect models, according to heterogeneity of included studies. In total, 50 studies with 6712 patients were recruited. Overall analysis showed that there was a significant reduction of CTC-positive rate (RR = 0...
March 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28330468/tumor-burden-monitoring-using-cell-free-tumor-dna-could-be-limited-by-tumor-heterogeneity-in-advanced-breast-cancer-and-should-be-evaluated-together-with-radiographic-imaging
#2
José Angel García-Saenz, Patricia Ayllón, Marion Laig, Daniel Acosta-Eyzaguirre, Marta García-Esquinas, Myriam Montes, Julián Sanz, Miguel Barquín, Fernando Moreno, Vanesa Garcia-Barberan, Eduardo Díaz-Rubio, Trinidad Caldes, Atocha Romero
BACKGROUND: Accurate measurement of tumor burden in breast cancer disease is essential to improve the clinical management of patients. In this study, we evaluate whether the fluctuations in the fraction of PIK3CA mutant allele correlates with tumor response according to RECIST criteria and tumor markers quantification. METHODS: Eighty six plasma samples were analyzed by digital PCR using Rare Mutation Assays for E542K, E545K and H1047R. Mutant cfDNA and tumor markers CA15-3 and CEA were compared with radiographic imaging...
March 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28325259/vitamin-d-analogues-potential-use-in-cancer-treatment
#3
REVIEW
Michael J Duffy, Alyson Murray, Naoise C Synnott, Norma O'Donovan, John Crown
The vitamin D receptor (VDR) is a member of the thyroid-steroid family of nuclear transcription factors. Following binding of the active form of vitamin D, i.e., 1,25(OH)2D3 (also known as calcitriol) and interaction with co-activators and co-repressors, VDR regulates the expression of several different genes. Although relatively little work has been carried out on VDR in human cancers, several epidemiological studies suggest that low circulating levels of vitamin D are associated with both an increased risk of developing specific cancer types and poor outcome in patients with specific diagnosed cancers...
April 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28290464/blocking-the-recruitment-of-naive-cd4-t-cells-reverses-immunosuppression-in-breast-cancer
#4
Shicheng Su, Jianyou Liao, Jiang Liu, Di Huang, Chonghua He, Fei Chen, LinBing Yang, Wei Wu, Jianing Chen, Ling Lin, Yunjie Zeng, Nengtai Ouyang, Xiuying Cui, Herui Yao, Fengxi Su, Jian-Dong Huang, Judy Lieberman, Qiang Liu, Erwei Song
The origin of tumor-infiltrating Tregs, critical mediators of tumor immunosuppression, is unclear. Here, we show that tumor-infiltrating naive CD4(+) T cells and Tregs in human breast cancer have overlapping TCR repertoires, while hardly overlap with circulating Tregs, suggesting that intratumoral Tregs mainly develop from naive T cells in situ rather than from recruited Tregs. Furthermore, the abundance of naive CD4(+) T cells and Tregs is closely correlated, both indicating poor prognosis for breast cancer patients...
March 14, 2017: Cell Research
https://www.readbyqxmd.com/read/28283696/myeloid-cells-in-circulation-and-tumor-microenvironment-of-breast-cancer-patients
#5
Salman M Toor, Azharuddin Sajid Syed Khaja, Haytham El Salhat, Issam Faour, Jihad Kanbar, Asif A Quadri, Mohamed Albashir, Eyad Elkord
Pathological conditions including cancers lead to accumulation of a morphological mixture of highly immunosuppressive cells termed as myeloid-derived suppressor cells (MDSC). The lack of conclusive markers to identify human MDSC, due to their heterogeneous nature and close phenotypical and functional proximity with other cell subsets, made it challenging to identify these cells. Nevertheless, expansion of MDSC has been reported in periphery and tumor microenvironment of various cancers. The majority of studies on breast cancers were performed on murine models and hence limited literature is available on the relation of MDSC accumulation with clinical settings in breast cancer patients...
March 10, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28282718/the-potential-of-circulating-tumor-cells-in-personalized-management-of-breast-cancer-a-systematic-review
#6
Fatemeh Khatami, Hamid Reza Aghayan, Maryam Sanaei, Ramin Heshmat, Seyed Mohammad Tavangar, Bagher Larijani
Circulating tumor cells (CTCs) recognition and characterization in the peripheral blood of patients with breast cancer have proven practical and predictive value in different studies. However, the clinical significance of CTCs enumeration and molecular characterization in thepersonalization of breast cancer diagnosis and treatment remains under the debate. A literature search in PubMed, Web of Science and Scopus was performed from October 1990 to June 2016 for studies which evaluating CTCs and its association with clinical and pathological characteristics and medical outcome in the field of breast cancer personalization for both diagnosis and treatment categories...
March 2017: Acta Medica Iranica
https://www.readbyqxmd.com/read/28275672/insulin-use-hormone-receptor-status-and-hematopoietic-cytokines-circulation-in-women-with-diabetes-mellitus-and-breast-cancer
#7
Zachary A P Wintrob, Jeffrey P Hammel, George K Nimako, Dan P Gaile, Alan Forrest, Alice C Ceacareanu
Granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) are cytokines of particular interest in oncology from the perspective of neutropenia management (Mehta et al., 2015 [1]) and also as indirect activators of tumor-associated macrophages and modifiers of tumor microenvironment. Associated with poor breast cancer survival and unfavorable hormone receptor status (Wintrob et al., 2017 [2]), insulin may also influence hematopoiesis, thus interfering with colony stimulating factor production...
April 2017: Data in Brief
https://www.readbyqxmd.com/read/28271309/mutational-studies-on-single-circulating-tumor-cells-isolated-from-the-blood-of-inflammatory-breast-cancer-patients
#8
Catherine Bingham, Sandra V Fernandez, Patricia Fittipaldi, Paul W Dempsey, Karen J Ruth, Massimo Cristofanilli, R Katherine Alpaugh
PURPOSE: The molecular characterization of circulating tumor cells (CTCs) is critical to identify the key drivers of cancer metastasis and devising therapeutic approaches, particularly for inflammatory breast cancer (IBC) which is usually diagnosed at advance stages and progresses rapidly. METHODS: Genomic alterations in tumor tissue samples were studied using Foundation One™. Single CTCs were isolated using CellSearch followed by single-cell isolation by DEPArray™...
March 7, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28268169/role-of-runx2-in-breast-cancer-mediated-bone-metastasis
#9
REVIEW
M Vishal, R Swetha, G Thejaswini, B Arumugam, N Selvamurugan
Breast cancer is one of the most prevalent forms of cancer in women. The currently available treatment for breast cancer is mostly curative except when it becomes metastatic. One of the major sites for metastasis of breast cancer is the bone. Homing of the circulating tumor cells is tightly regulated including a number of factors present in the cells and their microenvironment. Runx2, a transcription factor plays an important role in osteogenesis and breast cancer mediated bone metastases. One of the recent advances in molecular therapy includes the discovery of the small, non-coding microRNAs (miRNAs) and they target specific genes to reduce their expression at the post-transcriptional level...
March 6, 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/28266048/the-grhl2-zeb-feedback-loop-a-key-axis-in-the-regulation-of-emt-in-breast-cancer
#10
Steven M Mooney, Vida Talebian, Mohit Kumar Jolly, Dongya Jia, Monica Gromala, Herbert Levine, Brendan J McConkey
More than 90% of cancer-related deaths are caused by metastasis. Epithelial-to-Mesenchymal Transition (EMT) causes tumor cell dissemination while the reverse process, Mesenchymal-to-Epithelial Transition (MET) allows cancer cells to grow and establish a potentially deadly metastatic lesion. Recent evidence indicates that in addition to E and M, cells can adopt a stable hybrid Epithelial/Mesenchymal (E/M) state where they can move collectively leading to clusters of Circulating Tumor Cells - the 'bad actors' of metastasis...
March 7, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/28258988/serum-igf-1-igfbp-3-levels-and-circulating-tumor-cells-ctcs-in-early-breast-cancer-patients
#11
Georgios Z Papadakis, Dimitrios Mavroudis, Vasilios Georgoulias, John Souglakos, Athanasios K Alegakis, George Samonis, Ulas Bagci, Antonis Makrigiannakis, Odysseas Zoras
OBJECTIVE: Insulin-like growth factor (IGF)-axis is involved in human oncogenesis and metastasis development for various solid tumors including breast cancer. Aim of this study was to assess the association between IGF-1, IGF-binding protein-3 (IGFBP-3) serum levels and the presence of circulating tumor cells (CTCs) in the peripheral blood of women diagnosed with early breast cancer (EBC), before and after adjuvant chemotherapy. DESIGN: 171 patients with early-stage breast adenocarcinomas were retrospectively evaluated...
February 16, 2017: Growth Hormone & IGF Research
https://www.readbyqxmd.com/read/28255347/enhanced-blood-suspensibility-and-laser-activated-tumor-specific-drug-release-of-theranostic-mesoporous-silica-nanoparticles-by-functionalizing-with-erythrocyte-membranes
#12
Jinghan Su, Huiping Sun, Qingshuo Meng, Pengcheng Zhang, Qi Yin, Yaping Li
Mesoporous silica nanoparticles (MSNs), with their large surface area and tunable pore sizes, have been widely applied for anticancer therapeutic cargos delivery with a high loading capacity. However, easy aggregation in saline buffers and limited blood circulation lifetime hinder their delivery efficiency and the anticancer efficacy. Here, new multifunctional MSNs-supported red-blood-cell (RBC)-mimetic theranostic nanoparticles with long blood circulation, deep-red light-activated tumor imaging and drug release were reported...
2017: Theranostics
https://www.readbyqxmd.com/read/28253723/effect-of-small-and-radical-surgical-injury-on-the-level-of-different-populations-of-circulating-tumor-cells-in-the-blood-of-breast-cancer-patients
#13
E V Kaigorodova, N A Tarabanovskaya, M N Staheeva, O E Savelieva, L A Tashireva, E V Denisov, V M Perelmuter
Circulating tumor cells (CTCs) constitute a heterogeneous population. Some tumor cells are cancer stem cells (CSCs), while others are in the process of the epithelial-mesenchymal transition (EMT); however, most CTCs are neither stem cells nor in the EMT. This prospective study of 22 patients with nonspecific-type invasive carcinoma of the breast identified different populations of CTCs by flow cytometry in the blood of patients before biopsy, after biopsy and after surgical tumor removal without neoadjuvant chemotherapy...
March 3, 2017: Neoplasma
https://www.readbyqxmd.com/read/28238187/circulating-tumor-cells-clinical-validity-and-utility
#14
REVIEW
Luc Cabel, Charlotte Proudhon, Hugo Gortais, Delphine Loirat, Florence Coussy, Jean-Yves Pierga, François-Clément Bidard
Circulating tumor cells (CTCs) are rare tumor cells and have been investigated as diagnostic, prognostic and predictive biomarkers in many types of cancer. Although CTCs are not currently used in clinical practice, CTC studies have accumulated a high level of clinical validity, especially in breast, lung, prostate and colorectal cancers. In this review, we present an overview of the current clinical validity of CTCs in metastatic and non-metastatic disease, and the main concepts and studies investigating the clinical utility of CTCs...
February 25, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28224210/tumor-specific-regulatory-t-cells-in-the-bone-marrow-of-breast-cancer-patients-selectively-upregulate-the-emigration-receptor-s1p1
#15
Anchana Rathinasamy, Christoph Domschke, Yingzi Ge, Hans-Henning Böhm, Steffen Dettling, David Jansen, Felix Lasitschka, Ludmila Umansky, Markus H Gräler, Jennifer Hartmann, Christel Herold-Mende, Florian Schuetz, Philipp Beckhove
Regulatory T cells (Treg) hamper anti-tumor T-cell responses resulting in reduced survival and failure of cancer immunotherapy. Among lymphoid organs, the bone marrow (BM) is a major site of Treg residence and recirculation. However, the process governing the emigration of Treg from BM into the circulation remains elusive. We here show that breast cancer patients harbour reduced Treg frequencies in the BM as compared to healthy individuals or the blood. This was particularly the case for tumor antigen-specific Treg which were quantified by MHCII tumor peptide loaded tetramers...
February 21, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28208771/detecting-blood-based-biomarkers-in-metastatic-breast-cancer-a-systematic-review-of-their-current-status-and-clinical-utility
#16
REVIEW
A M Sofie Berghuis, Hendrik Koffijberg, Jai Prakash, Leon W M M Terstappen, Maarten J IJzerman
Reviews on circulating biomarkers in breast cancer usually focus on one single biomarker or a selective group of biomarkers. An overview summarizing the discovery and evaluation of all blood-based biomarkers in metastatic breast cancer is lacking. This systematic review aims to identify the available evidence of known blood-based biomarkers in metastatic breast cancer, regarding their clinical utility and state-of-the-art position in the validation process. The initial search yielded 1078 original studies, of which 420 were assessed for eligibility...
February 9, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28197635/fluid-shear-stress-induces-cancer-stem-cell-like-phenotype-in-mcf7-breast-cancer-cell-line-without-inducing-epithelial-to-mesenchymal-transition
#17
Ursula L Triantafillu, Seungjo Park, Nikki L Klaassen, Andrew D Raddatz, Yonghyun Kim
Metastasis is the leading cause of cancer deaths due to the spread of cancer cells through the blood vessels and the subsequent formation of secondary tumors. Metastasizing cancer cells in the human vasculature are called circulating tumor cells (CTCs) and are characterized to express the epithelial cell adhesion molecule (EpCAM). They are further known to survive physiological fluid shear stress (FSS) conditions. However, the effect of FSS on CTC molecular phenotype, such as the epithelial to mesenchymal transition (EMT) and cancer stem cell (CSC) expression, has not been extensively studied...
March 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28190761/prevalence-of-circulating-tumor-cells-after-adjuvant-chemotherapy-with-or-without-anthracyclines-in-patients-with-her2-negative-hormone-receptor-positive-early-breast-cancer
#18
Amelie Schramm, Fabienne Schochter, Thomas W P Friedl, Nikolaus de Gregorio, Ulrich Andergassen, Marianna Alunni-Fabbroni, Elisabeth Trapp, Bernadette Jaeger, Georg Heinrich, Oumar Camara, Thomas Decker, Angelika Ober, Sven Mahner, Tanja N Fehm, Klaus Pantel, Peter A Fasching, Andreas Schneeweiss, Wolfgang Janni, Brigitte K Rack
BACKGROUND: Use of anthracycline-based chemotherapy in patients with early breast cancer (EBC) has been well-established but is often associated with cardiotoxicity. Based on data suggesting a limited benefit of anthracyclines in human epidermal growth factor receptor 2 (HER2)-negative patients, the Simultaneous Study of Docetaxel Based Anthracycline Free Adjuvant Treatment Evaluation, as well as Life Style Intervention Strategies (SUCCESS) C study randomized patients to either anthracycline-containing or anthracycline-free chemotherapy...
January 10, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28187533/comparison-of-analytic-performances-of-cellsearch-and-ifish-approach-in-detecting-circulating-tumor-cells
#19
Yuan Sheng, Ting Wang, Hengyu Li, Zhenzhen Zhang, Jianghao Chen, Chenyang He, Yongping Li, Yonggang Lv, Juliang Zhang, Cheng Xu, Zhen Wang, Chen Huang, Ling Wang
Circulating tumor cells (CTCs) have been widely used to predict the prognosis of breast cancer patients. The aim of the present study was to compare the performances of Cellsearch and immunostaining-fluorescence in situ hybridization (iFISH) in detecting CTCs in breast cancer patients. Forty-five newly diagnosed breast cancer patients and 14 healthy donors were recruited and their CTCs were detected by both Cellsearch and iFISH. Correlation between clinicopathological features and CTCs was investigated. We found that the positive rate of CTC detected by iFISH was significantly higher than by Cellsearch system (91% vs 38%)...
January 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/28181129/circulating-tumor-cells-as-a-prognostic-marker-for-efficacy-in-the-randomized-phase-iii-jo21095-trial-in-japanese-patients-with-her2-negative-metastatic-breast-cancer
#20
Hiroji Iwata, Norikazu Masuda, Daigo Yamamoto, Yoshiaki Sagara, Nobuaki Sato, Yutaka Yamamoto, Mitsue Saito, Takashi Fujita, Shoji Oura, Junichiro Watanabe, Masami Tsukabe, Kazumi Horiguchi, Satoshi Hattori, Yoshimasa Matsuura, Katsumasa Kuroi
PURPOSE: Prognostic effects of circulating tumor cells (CTCs) have been reported in metastatic breast cancer (MBC). However, few phase III trials have investigated the potential role of CTCs in treatment selection. We explored potential relationships between CTCs, efficacy, and differential treatment effects. METHODS: Patients with HER2-negative MBC were randomized to receive either concurrent capecitabine plus docetaxel (XT) or sequential single-agent docetaxel followed by single-agent capecitabine at progression (T → X)...
February 8, 2017: Breast Cancer Research and Treatment
keyword
keyword
99352
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"